AC Immune SA Inc. (NASDAQ: ACIU) stock declined by 5.29% in the current market trading session. AC Immune SA is a clinical-stage pharmaceutical company with the goal of becoming a world leader in targeted therapy for neurodegenerative illnesses such as Alzheimer’s, Parkinson’s, and NeuroOrphan indications caused by misfolded proteins.
ACIU stock’ Current Update
At the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happened in Boston, Massachusetts from November 9-12, 2021, AC Immune SA presented different interim Phase 1b/2a data on ACI-35.030. It is a first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate being made in conjunction with Janssen Pharmaceuticals, Inc.
ACI-35.030 is the first Alzheimer’s disease vaccine candidate to produce antibodies against pathogenic pTau in the brain. At CTAD, AC Immune’s Chief Medical Officer Johannes Streffer presented findings from a current, placebo-controlled Phase 1b/2a trial testing ACI-35.030 in patients with early Alzheimer’s disease in an on-demand oral presentation (AD). The trial found that ACI-35.030 therapy resulted in a significant increase of antibodies specific for pathogenic forms of Tau, such as pTau and its aggregated form, as well as an enrichment of paired helical filaments (ePHF).
Prof. Andrea Pfeifer, CEO of AC Immune SA, stated that,
The discovery of such a powerful and long-lasting immune response to a self-protein in an aged population is both remarkable and significant in terms of altering the AD therapy paradigm toward early treatment and prevention. Many years before the Tau build-up was evident using imaging modalities, pathological pTau is present in the CSF as a precursor. They hope to fulfill the significant promise which this anti-pTau vaccination has shown as a viable early intervention for AD by developing ACI-35.030 while harnessing cutting-edge Tau diagnostics.They are excited to continue working with Janssen Pharmaceuticals, Inc. and to share new immunogenicity results from the high-dose group in Phase 1b/2a trial.
